Novel antipsychotic agents with dopamine autoreceptor agonist properties: Synthesis and pharmacology of 7-[4-(4-phenyl-1- piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives

Journal of Medicinal Chemistry

Volumn 41, Issue 5, 1998, Pages 658-667

  Oshiro, Yasuo ^a   Sato, Seiji ^a   Kurahashi, Nobuyuki ^a   Tanaka, Tatsuyoshi ^a   Kikuchi, Tetsuro ^a   Tottori, Katsura ^a   Uwahodo, Yasufumi ^a   Nishi, Takao ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; ARIPIPRAZOLE; DOPAMINE AUTORECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; GAMMA BUTYROLACTONE; LEVODOPA; NEUROLEPTIC AGENT; POSTSYNAPTIC RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PSYCHOPHARMACOLOGY; STEREOTYPY; STRUCTURE ACTIVITY RELATION;

4-BUTYROLACTONE; ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BRAIN; CATALEPSY; DIHYDROXYPHENYLALANINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; GABA MODULATORS; MALE; MICE; MICE, INBRED ICR; MOLECULAR STRUCTURE; PIPERAZINES; QUINOLONES; RATS; STEREOTYPED BEHAVIOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032567924     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm940608g     Document Type: Article

References (47)

1. Jannsen, P. A.; Niemergars, C, J. E.; Schellenkens, K. H. K. Is It Possible to Predict the Clinical Effects of Neuroleptic Drugs (Majortranquilizers) from Animal Data? Arzneim-Forsch. (Drug Res.) 1965, 15, 104.
2. Simpson, G. M.; Pi, E. H.; Sramek, J. J. Adverse Effects of Antipsychotic Agents. Drugs 1981, 21, 138-151.
3. Simpson, G. M.; Pi, E. H.; Sramek, J. J. Management of Tardive Dyskinesia: Current Update. Drugs 1982, 23, 381-393.
4. Carlsson, A. Receptor-Mediated Control of Dopamine Metabolism. In Pre- and Postsynaptic Receptor, Usdin, E., Bunny, W. E., Eds.; Marcel Dekker: New York, 1975; pp 49-65.
5. 2-Autoreceptor Agonists with Special Reference to Indolylbutylamines. Drugs Future 1990, 15, 819-832.
6. Caprathe, B. W.; Jaen, J. C.; Wise, L. D.; Heffner, T. G.; Dugsley, T. A.; Meltzen, L. T.; Parvez, M. Dopamine Autoreceptor Agonist as Potential Antipsychotics. 3. 6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine. J. Med. Chem. 1991, 34, 2736-2746.
7. Hacksell, U.; Arvidsson, L.; Svensson, U.; Nilsson, J. L. G.; Sanchez, D.; Wickström, H.; Lindberg, P.; Hjorth, S.; Carlsson, A. 3-Phenylpiperidines. Central Dopamine-Autoreceptor Stimulating Activity. J. Med. Chem. 1931, 24, 1475-1482.
8. Jaen, J. C.; Wise, L. D.; Heffner, T. G.; Dugsley, T. A.; Meltzen, L. T. Dopamine Autoreceptor Agonist as Potential Antipsychotics. 1. (Aminoalkoxy)anilines. J. Med. Chem. 1988, 31, 1621- 1625.
9. Banno, K.; Fujioka, T.; Kikuchi, T.; Oahiro, Y.; Hiyama, T.; Nakagawa, K. Studies on 2(1H)-Quinolinone Derivatives as Neuroleptic Agents I. Synthesis and Biological Activities of (4- Phenyl-1-piperazinyl)propoxy-2(1H)-quinolinone Derivatives. Chem. Pharm. Bull. 1988, 36, 4377-4388.
10. Kikuchi, K.; Hirata, Y.; Minami, M.; Nagatsu, T. Effects of 7-[3- [4-(2,3-Dimethylphenyl)-piperazinyl]propoxy]-2(1H)-quinolinone (OPC-4392), A Newly Synthesized Agonist for Presynaptic D2-Receptor, on Tyrosine Hydroxylation in Rat Striatal Slice. Life Sci. 1988, 42, 343-349.
11. 2-Receptor Antagonist. Life Sci. 1988, 42, 1941-1954.
12. Sasa, M.; Ohno, Y.; Takaori, S. Presynaptic Inhibition of Excitatory Input from the Substantia Nigra to Caudate Nucleous Neurons by a Substituted Quinoline Derivative, 7-[3-[4-(2,3- Dimethylphenyl)-piperazinyl]propoxy]-2(1H)-quinolinone (OPC- 4392). Life Sci. 1988, 43, 263-269.
13. Akaike, A.; Ohno, Y.; Sasa, M.; Takaori, S. Excitatory and Inhibitory Effects of Dopamine on Neuronal Activity of the Caudate Nucleous Neurons in vitro. Brain Res. 1987, 478, 262- 272.
14. 2-Receptor-Mediated Inhibition by a Substituted Quinolinone Derivative, 7-[3-[4-(2,3- Dimethylphenyl)piperazinyl]propoxy]-2(1H)quinolinone (OPC- 4392), of Dopaminergic Neurons in the Vental Tegmental Area. Life Sci. 1990, 47, 761-769.
15. 3H-SCH 23390 Binding in Rat Striatum: Effects of Lesions. Pharm. Res. 1990, 7, 280- 282.
16. Lipka, G.; Woedemann, K.; Benkert, O.; Holsboer, F. Presynaptic Dopamine Receptor Agonist (B-HT-920): Treatment of Schizophrenia. Psychopharmacology (Suppl.) 1988, 96, 333.
17. Klimke, A.; Klieser, E. Antipsychotic Efficacy of the Dopaminergic Autoreceptor Agonist EMD 49980 (Roxindol). Pharmacopsychiat. 1991, 24, 107-112.
18. Olbrich, R.; Schanz, H. The Effects of the Partial Dopamine Agonist Terguride on Negative Symptoms in Schizophrenics. Pharmacopsychiat. 1988, 21, 389-390.
19. Seeman, P.; Lee, T.; Chau-Wong, M.; Wong, K. Antipsychotic Drug Does and Neuroleptic/Dopamine Receptors. Nature (London) 1976, 261, 717-719.
20. Seeman, P. Brain Dopamine Receptors. Pharmacol. Rev. 1980, 32, 229-313.
21. Creese, I.; Burt, D. R.; Snyder, S. H. Dopamine Receptors and Average Clinical Doses. Science 1976, 192, 481-483.
22. Puech, A. J.; Riox, P.; Poncelet, M.; Brochet, D.; Chermat, R.; Simon, P. Pharmacological Properties of New Antipsychotic Agents: Use of Animal Models. Neuropharmacology 1981, 1279-1284.
23. Walters, J. R.; Roth, R. H. Dopaminergic Neurons: Drug-Induced Antagonism of the Increase in Tyrosine Hydroxylase Activity Produced by Cessation of Impulse Flow. J. Pharmacol. Exp. Ther. 1974, 191, 82-91.
24. Walters, J. R.; Roth, R. H. Dopaminergic Neurons: An in vivo System for Measuring Drug Interactions with Presynaptic Receptors. Naunyn-Schmiederberg's Arch. Pharmacol. 1976, 296, 5-14.
25. Nakagawa, K.; Uchida, M.; Oka, K. (Haloalkyloxy)carbostyrils. Japan Kokai JP 75-58125; Chem. Abstr. 1977, 87, 84841g.
26. Nishi, T.; Yamamoto, K.; Shimizu, T.; Kanbe, T.; Kimura, Y.; Nakagawa, K. Studies on 2-Oxoquinoline Derivatives as Blood Platelet Aggregation Inhibitors. I. Alkyl 4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butylates and Related Compounds. Chem. Pharm. Bull. 1983, 31, 798-810.
27. Creese, I.; Burt, D. R.; Snyder, S. H. Dopamine Receptors and Average Clinical Doses. Science 1976, 192, 481-483.
28. Richelson, E. Neuroleptic Affinities for Human Brain Receptors and Their Use in Predicting Adverse Effects. J. Clin. Psychiat. 1984, 45, 331-336.
29. Andrew, F.; Rennie, C. H. Clozapine: A Review of Its Pharmacological Properties and Therapeutic Use in Schizophrenia. 1. Drugs 1990, 40 (5), 722-747.
30. 2 Receptor Antagonistic Activity. J. Pharmacol. Exp. Ther. 1995, 274 (1), 329-336.
31. Hornykiewicz, O. Brain Catecholeamines in Schizophrenia: A Good Case for Noradrenaline. Nature 1982, 299, 484.
32. Masson, S. T. Designing a Non-Neuroleptic Antischizophrenic Drug: The Noradrenergic Strategy. Trends Pharmacol. Sci. 1983, 4, 353.
33. An Kammen, D. P.; Antelman, S. Minireview: Impaired Noradrenergic Transmission in Schizophrenia? Life Sci. 1984, 34, 1403.
34. Amano, T.; Matsubayashi, H.; Momiyama, T.; Ishihara, K.; Todo, N.; Sasa, M. Antagonizing Effect of Novel Antipsychotic Quinolinone Derivative (OPC-14597) on Dopaminergic Inhibition of Neuronal Activities in the Nucleus Accumbens. Prog. Neuropsychopharm. Biol. Psychiat. 1995, 19 (1), 105-116.
35. Murasaki, M. Recent Progress in Development of Psychotropic Drugs (2): Antipsychotics. Nihon Shinkei Seishin Yakurigaku Zasshi 1995, 15 (3), 191-210.
36. Semba, J.; Watanabe, A.; Kito, S.; Toreu, M. Behavioral and Neurochemical Effects of OPC-14597, a Novel Antipsychotic Drug, on Dopaminergic Mechanism in Rat Brain. Neuropharmacology 1995, 34 (7), 785-791.
37. Inoue, T.; Domae, M.; Yamada, K.; Furukawa, T. Effects of the Novel Antipsychotic Agent 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on Prolactin Release from the Rat Anterio Pitutary Gland. J. Pharmacol. Exp. Ther. 1996, 277 (1), 137-143.
38. Fujikawa, M.; Nagashima, M.; Inoue, T.; Yamada, K.; Furukawa, T. Partial Agonistic Effects of OPC-14597, a Potential Antipsychotic Agent, on Yawning Behavior in Rats. Pharmacol. Biochem. Behav. 1996, 53 (4), 903-909.
39. Momiyama, T.; Amano, T.; Todo, N.; Sasa, M. Inhibition by a Putative Antipsychotic Quinolinone Derivative (OPC-14597) of Dopaminergic Neurons in the Ventaral Tergmental Area. Eur. J. Pharmacol. 1996, 310 (1), 1-8.
40. Semba, J.; Sakai, M.; Miyoshi, R.; Mataga, N.; Fukamachi, F.; Kito, S. Differential Expression of c-fos mRNA in Rat Prefrontal Cortex, Striatum, N. Accumbens and Lateral Septum after Typical and Atypical Antipsychotics: an in situ Hybridization Study. Neurochem. Int. 1996, 29 (4), 435-442.
41. Yamada, S.; Harano, M.; Yokoo, H.; Tanaka, M. Antagonistic Effects of OPC-14597, a Novel Antipsychotic Drug, on Quinpiroland (-)-Sulpiride-induced Changes in Evoked Dopamine Release in Rat Striatal Slices. J. Pharm. Pharmacol. 1997, 49 (2), 206- 208.
42. Pollard, C. B.; Wicker, H. T., Jr. Derivatives of Piperazine. XXIV. Synthesis of 1-Arylpiperazines and Amino Alcohol Derivatives. J. Am. Chem. Soc. 1954, 76, 1853-1855.
43. Otsubo, J.; Furubayashi, K.; Nakagawa, K.; Higuchi, S. Preparation of Phenylpiperazine Derivatives. Jpn. Kokai Tokkyo Koho JP 82-42, 679 Chem. Abstr. 1982, 97, 92317n.
44. Matsuyama, T.; Watanabe, N. Preparation Method of Phenylpiperazine Derivatives. Jpn. Kokai Tokkyo Kouhou JP 85-41670, Koei Chemical Co. Ltd.; Chem. Abstr. 1985, 103, 87905r.
45. Matsuyama, T.; Watanabe, N. Preparation Method of Phenylpiperazine Derivatives. Jpn. Kokai Tokkyo Kouhou JP 85-41670, Koei Chemical Co. Ltd.; Chem. Abstr. 1985, 103, 87905r.
46. Yevich, P. J.; New, S. J.; Lobeck, G. W.; Dextraze, P.; Bernstein, E.; Taylor, P. D.; Yocca, D. F.; Eison, S. M.; Temple, L. D., Jr. Synthesis and Biological Characterization of α-(4-Fluorophenyl)- 4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and Analogues as Potential Atypical Antipsychotic Agents. J. Med. Chem. 1992, 35, 4516-4525.
47. Westerich, B. H. C.; Mulder, T. B. A. Determination of Picomole Amounts of Dopamine, Noradrenaline, 3,4-Dihydroxyphenylalanine, 3,4-Dihydroxyphenylacetic Acid, Homovanillic Acid and 5-Hydroxy-indoleacetic Acid in Nervous Tissue after One-step Purification on Sephadex G-10, Using High-Performance Liquid Chromatography with a Novel Type of Electrochemical Detection. Neurochemistry 1981, 36, 1449-146.